Nyxoah SA (NYXH) Earnings Date & Reports

Key Takeaways

• Global net revenue reached €9.2 million in the third quarter of 2026, up 365% year over year and 19% sequentially, driven by U.S. net revenue of €6.7 million.
• Gross margin improved to 63.1% from 60.5% a year earlier, while the operating loss narrowed to €21.9 million from €24.4 million.
• Management lowered full-year 2026 revenue guidance to €33 million–€35 million from a prior range of €36 million–€40 million.
• U.S. commercial momentum continued, with 80 new surgeons trained and 53 new accounts activated during the quarter.
• The company submitted a premarket approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) to expand the Genio system's indication to patients with complete concentric collapse.
• For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages.
• Discover Trending AI Robots to see how AI-driven tools are being applied across the market.

Earnings Context and Why It Matters

Nyxoah SA is a Belgian medical technology company commercializing the Genio system, a bilateral hypoglossal nerve stimulation (HGNS) therapy for obstructive sleep apnea (OSA), a common sleep-disordered breathing condition linked to cardiovascular risks. The third quarter of 2026 is a pivotal checkpoint in the company's U.S. commercial launch, which began after FDA approval in August 2025. Investors are closely watching how quickly the U.S. ramp scales, whether reimbursement coverage expands, and whether clinical milestones broaden the addressable patient population. The results matter because they signal whether Nyxoah can convert regulatory success into durable revenue growth while narrowing losses in a market dominated by larger competitors.

Reported Results

For the third quarter ended September 30, 2026, Nyxoah reported global net revenue of €9.2 million, a 365% increase from €2.0 million in the prior-year period and up 19% sequentially. U.S. net revenue was €6.7 million, up 29% from the second quarter, while international revenue rose 42% year over year to €2.5 million. Gross margin expanded to 63.1% from 60.5% a year earlier, helped by spreading costs over higher device volumes.

The total operating loss narrowed to €21.9 million from €24.4 million, and the net loss improved to €17.8 million from €23.6 million. Loss per share was €0.177, compared with €0.630 in the third quarter of 2025. Cash, cash equivalents, and financial assets totaled €77.1 million at quarter-end, down from €97.8 million at June 30, 2026.

On guidance, management trimmed its full-year 2026 revenue outlook to €33 million–€35 million from €36 million–€40 million, while maintaining a full-year gross margin expectation of 60%–62%. The revision had been signaled in an October 19 pre-announcement and reflected a U.S. ramp tracking a more typical adoption curve for new medical technology.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending names, breakout candidates, and market opportunities more efficiently than manual screening. Investors following companies such as Nyxoah can use it to monitor the broader medical technology landscape and identify related opportunities.

Market Reaction and Investor Sentiment

Because the company pre-announced preliminary third-quarter revenue and the guidance cut on October 19, much of the market's reaction was already priced in ahead of the November 5 final results. Sentiment heading into the report balanced accelerating U.S. revenue growth against the reduced full-year outlook. The clinical news was a notable positive: the ACCCESS U.S. pivotal study met its efficacy and safety endpoints in complete concentric collapse (CCC) patients, with a 12-month Apnea-Hypopnea Index (AHI) responder rate of 77.2% and zero device- or procedure-related serious adverse events. This supported a PMA supplement to broaden the U.S. indication, potentially expanding the addressable market beyond patients currently contraindicated for available unilateral stimulation options.

Forward Outlook and Key Factors to Monitor

Investors should watch several catalysts in the coming quarters. The first is the pace of U.S. utilization: Nyxoah reported 342 surgeons trained, 233 active accounts, and 447 patients under prior authorization entering the fourth quarter. Converting that pipeline into implants will be central to meeting the revised revenue target.

Reimbursement is another key variable. The Centers for Medicare & Medicaid Services (CMS) published its 2027 final rule, raising hospital outpatient reimbursement for the Genio procedure from $31,526 to $35,072 and ambulatory surgical center reimbursement from $27,563 to $31,283. These increases strengthen the procedure's economic appeal to facilities.

Regulatory progress also warrants attention. An FDA decision on the PMA supplement for CCC patients could meaningfully widen the treatable population. Finally, cost discipline remains important as the company shifts spending from research and development toward commercial infrastructure while seeking to reduce cash burn quarter over quarter.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations